Whalesbook
MSN Seals Generic Deal, Secures Myrbetriq Rights
MSN Pharmaceuticals finalized a $75 million upfront settlement with Astellas Pharma for U.S. marketing rights to a generic mirabegron drug, known as Myrbetriq. The deal resolves patent disputes over formulation and 'food-effect' details, allowing MSN to keep selling its generic version. Astellas secured a large upfront payment and will receive per-unit licensing fees as the drug approaches its patent expiry. This is the third such settlement Astellas has made with Indian drugmakers, after earlier deals with Lupin and Zydus Lifesciences.
New Deal Terms Spark Rival Concerns
MSN's settlement terms are under scrutiny because they may be more favorable than those previously agreed upon by Lupin and Zydus. Lupin's earlier deal was for roughly $90 million ($75 million upfront), and Zydus committed $120 million. Both also agreed to licensing fees until September 2027. The market reacted quickly: Zydus Lifesciences shares dropped 2.37% and Lupin shares fell 2.03% on the BSE. Investors worry MSN's potentially lower costs will speed up competition, limiting profits for Lupin and Zydus in the U.S. mirabegron market, which is worth about $1 billion. Astellas noted the financial effects would appear in its fiscal year 2027 guidance.
Market Reaction and Financial Context
Lupin and Zydus Lifesciences faced complex patent litigation with Astellas over generic mirabegron. Though initial court rulings favored them, an appeals court raised questions, and a Delaware court later upheld Astellas's patent validity in March 2026. This led to settlements, including Lupin's $90 million and Zydus's $120 million deals in February 2026, intended to secure sales and offer a period of limited competition. However, MSN's entry with potentially better terms could shorten this competitive window.
Lupin's market capitalization is around ₹1.06 trillion INR (P/E 22.65x-24.2x), and Zydus Lifesciences is about ₹95,000 crore INR (P/E 19.00x-20.06x). The Indian pharma sector faces U.S. market headwinds, with slower growth expected due to pricing pressures. While Lupin anticipated stronger U.S. growth from mirabegron and tolvaptan, the U.S. Overactive Bladder (OAB) market, valued at $1.078 billion in 2024, is projected to grow modestly. Astellas Pharma holds a significant share in this market.
Analyst Views: Settlements Offer Limited Solace
Analyst firm UBS maintained 'Sell' ratings for Lupin and Zydus on March 25, 2026. They cited the companies' reliance on one-time patent settlement income and a lack of diverse growth drivers in competitive areas like GLP-1 drugs. Though settlements cleared legal uncertainties, MSN's potentially better deal could reduce the anticipated advantages of limited competition and hurt margins. Before settlements, Zydus's mirabegron sales were estimated at $35 million quarterly, and Lupin's at $25–30 million. Increased U.S. generic price erosion, rising costs, and compliance expenses may decrease profits from these deals faster than expected. Challenging innovator patents carries significant risks.
Looking Ahead: Diversification is Crucial
MSN's new settlement structure for U.S. generic mirabegron adds more competition, potentially undermining the short-term benefits of recent deals for Lupin and Zydus. While settlements helped manage litigation risks and maintain market access, their long-term value will depend on how well Lupin and Zydus diversify their products and revenue. Analysts warn that relying on these single-product settlements for growth is not a long-term strategy, especially with ongoing U.S. price pressures. Lupin and Zydus must strategically manage their OAB treatments and explore new areas to succeed in this changing market.